Latest Breaking News On - Interim results after - Page 1 : comparemela.com

/PRNewswire/ UCB, a global biopharmaceutical company, today announced new data on its investigational IL-17A and IL-17F inhibitor, bimekizumab, and its TNF.

Bruxelles capitaleNicole hergaCertolizumab pegolJ clin pharmacolAntje witteHead of immunology medical affairsGroup of companiesAmerican college of rheumatology convergenceDrug administrationTerm improvements in healthSource ucb incJeffrey starkLong term safetyAnkylosing spondylitisInterim results afterOngoing phase